Advertisement

Brain Tumor Pathology

, Volume 31, Issue 4, pp 265–273 | Cite as

Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases

  • Siraj El Jamal
  • Shiyong Li
  • Renu Bajaj
  • Zixuan Wang
  • Lawrence Kenyon
  • Jon Glass
  • Changlee S. Pang
  • Sharathkumar Bhagavathi
  • Stephen C. Peiper
  • Jerald Z. Gong
Original Article

Abstract

We report five cases of primary central nervous system (CNS) Epstein–Barr virus (EBV)-positive lymphoma of the elderly. This represented an incidence of 4 % of primary CNS diffuse large B-cell lymphoma (DLBCL) after EBV screening in 134 cases. All five patients were 65 years or older with no previous history of congenital or iatrogenic immune deficiencies. The histologic morphology of all the cases was DLBCL, with variable amounts of necrosis. The cell of origin (COO) as determined by the Hans algorithm disclosed germinal center type in 2 cases and non-germinal center type in 3 cases. MYC translocation was not detected, and MYC overexpression was detected in only one case. Three patients died shortly after diagnosis, and the remaining 2 patients were in complete remission for 2 and 10 years, respectively. We conclude that EBV+ DLBCL among the elderly is uncommon in primary CNS lymphoma in the Eastern United States. The patients usually present with a single mass lesion with headache and sensorimotor symptoms. The histologic morphology is DLBCL, but clonal T-cell gene rearrangement may be detected. The outcome varies from case to case and appears to be unrelated to the COO or MYC status.

Keywords

Epstein–Barr virus Central nervous system Diffuse large B-cell lymphoma Elderly 

References

  1. 1.
    Nakamura S, Jaffe ES, Swerdlow SH (2008) EBV positive diffuse large B-cell lymphoma of the elderly. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, pp 243–244Google Scholar
  2. 2.
    Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, Yokoi T, Kojima M, Kamiya Y, Taji H, Kagami Y, Ogura M, Saito H, Morishima Y, Nakamura S (2003) Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16–26PubMedCrossRefGoogle Scholar
  3. 3.
    Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M (2000) The characteristics of Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(−) cases in Japanese population. Jpn J Cancer Res 91:1233–1240PubMedCrossRefGoogle Scholar
  4. 4.
    Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS (2007) The impact of Epstein–Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110:972–978PubMedCrossRefGoogle Scholar
  5. 5.
    Adam P, Bonzheim I, Fend F, Quintanilla-Martinez L (2011) Epstein–Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 18:349–355PubMedCrossRefGoogle Scholar
  6. 6.
    Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M, Hills RK, Jaffe ES (2011) Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 117:4726–4735PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosia SG, Mazorra F, Castillo ME, Lopez M, Pajares R, Garcia JF, Mollejo M, Camacho FI, Ruiz-Marcellan C, Adrados M, Ortiz N, Franco R, Ortiz-Hidalgo C, Suarez-Gauthier A, Young KH, Piris MA (2012) EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 25:968–982PubMedCrossRefGoogle Scholar
  8. 8.
    Morgello S (1992) Epstein–Barr and human immunodeficiency viruses in acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Am J Pathol 141:441–450PubMedPubMedCentralGoogle Scholar
  9. 9.
    Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ (2004) Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 121:246–253PubMedCrossRefGoogle Scholar
  10. 10.
    Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, Dogan A, Giannini C (2008) Epstein–Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol 67:1103–1111PubMedCrossRefGoogle Scholar
  11. 11.
    Lucantoni C, De Bonis P, Doglietto F, Esposito G, Larocca LM, Mangiola A, Martini M, Papacci F, Teofili L, Pompucci A (2009) Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. J Neurooncol 94:235–242PubMedCrossRefGoogle Scholar
  12. 12.
    List AF, Greer JP, Cousar JP, Johnson DH, Greco FA, Volsky DJ, Purtilo DT (1990) Primary brain lymphoma in the immunocompetent host: relation to Epstein–Barr virus. Mod Pathol 3:609–612PubMedGoogle Scholar
  13. 13.
    Kluin PM, Deckert M, Ferry JA (2008) Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, pp 240–241Google Scholar
  14. 14.
    Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282PubMedCrossRefGoogle Scholar
  15. 15.
    Utsuki S, Oka H, Miyajima Y, Kijima C, Yasui Y, Fujii K (2011) Epstein–Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time? Brain Tumor Pathol 28:145–149PubMedCrossRefGoogle Scholar
  16. 16.
    Camilleri-Broet S, Martin A, Moreau A, Angonin R, Henin D, Gontier MF, Rousselet MC, Caulet-Maugendre S, Cuilliere P, Lefrancq T, Mokhtari K, Morcos M, Broet P, Kujas M, Hauw JJ, Desablens B, Raphael M (1998) Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d’etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 110:607–612PubMedGoogle Scholar
  17. 17.
    Gualco G, Weiss LM, Barber GN, Bacchi CE (2011) Diffuse large B-cell lymphoma involving the central nervous system. Int J Surg Pathol 19:44–50PubMedCrossRefGoogle Scholar
  18. 18.
    Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288PubMedCrossRefGoogle Scholar
  19. 19.
    Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, Lavagetto G, Casti A, Franceschi C, Passeri M, Sansoni P (2000) Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 95:2860–2868PubMedGoogle Scholar
  20. 20.
    Ouyang Q, Wagner WM, Walter S, Muller CA, Wikby A, Aubert G, Klatt T, Stevanovic S, Dodi T, Pawelec G (2003) An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein–Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev 124:477–485PubMedCrossRefGoogle Scholar
  21. 21.
    Gibson SE, Hsi ED (2009) Epstein–Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 40:653–661PubMedCrossRefGoogle Scholar
  22. 22.
    Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S (2010) Epstein–Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 41:352–357PubMedCrossRefGoogle Scholar
  23. 23.
    Hofscheier A, Ponciano A, Bonzheim I, Adam P, Lome-Maldonado C, Vela T, Cortes E, Ortiz-Hidalgo C, Fend F, Quintanilla-Martinez L (2011) Geographic variation in the prevalence of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 24:1046–1054PubMedCrossRefGoogle Scholar
  24. 24.
    Gong JZ, Stenzel TT, Bennett ER, Lagoo AS, Dunphy CH, Moore JO, Rizzieri DA, Tepperberg JH, Papenhausen P, Buckley PJ (2003) Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol 27:818–827PubMedCrossRefGoogle Scholar
  25. 25.
    Ibrahim HA, Menasce LP, Pomplun S, Burke M, Bower M, Naresh KN (2011) Presence of monoclonal T-cell populations in B-cell post-transplant lymphoproliferative disorders. Mod Pathol 24:232–240PubMedCrossRefGoogle Scholar
  26. 26.
    Theriault C, Galoin S, Valmary S, Selves J, Lamant L, Roda D, Rigal-Huguet F, Brousset P, Delsol G, Al Saati T (2000) PCR analysis of immunoglobulin heavy chain (IgH) and TcR-gamma chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases. Mod Pathol 13:1269–1279PubMedCrossRefGoogle Scholar
  27. 27.
    Slack GW, Gascoyne RD (2011) MYC and aggressive B-cell lymphomas. Adv Anat Pathol 18:219–228PubMedCrossRefGoogle Scholar
  28. 28.
    Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E, Kluin PM (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152–3162PubMedGoogle Scholar
  29. 29.
    van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC, Kluin PM (2006) Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24:4135–4142PubMedCrossRefGoogle Scholar
  30. 30.
    Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, Micallef IN, Dogan A, Witzig TE (2012) Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood 120:4400–4406PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Moller MB, Medeiros LJ, Young KH (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021–4031PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2014

Authors and Affiliations

  • Siraj El Jamal
    • 1
  • Shiyong Li
    • 2
  • Renu Bajaj
    • 1
  • Zixuan Wang
    • 1
  • Lawrence Kenyon
    • 1
  • Jon Glass
    • 3
  • Changlee S. Pang
    • 4
  • Sharathkumar Bhagavathi
    • 5
  • Stephen C. Peiper
    • 1
  • Jerald Z. Gong
    • 1
  1. 1.Department of Pathology, Anatomy and Cell BiologyThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Department of Pathology and Laboratory MedicineEmory UniversityAtlantaUSA
  3. 3.Jefferson Hospital for NeuroscienceThomas Jefferson UniversityPhiladelphiaUSA
  4. 4.Department of PathologyWake Forest UniversityWinston-SalemUSA
  5. 5.Department of PathologyUniversity of Medicine and Dentistry New JerseyNew BrunswickUSA

Personalised recommendations